Stem definition | Drug id | CAS RN |
---|---|---|
analogues of penicillanic acid antibiotics modified in the five-membered ring | 1046 | 153832-46-3 |
Dose | Unit | Route |
---|---|---|
1 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 38 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 28.72 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.12 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.45 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.10 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 3.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 18, 2002 | EMA | Merck Sharp & Dohme Ltd | |
Nov. 21, 2001 | FDA | MERCK SHARP DOHME |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Macular degeneration | 612.71 | 22.52 | 159 | 4317 | 14229 | 50586419 |
Seizure | 139.70 | 22.52 | 101 | 4375 | 117773 | 50482875 |
Hallucination | 121.52 | 22.52 | 66 | 4410 | 46591 | 50554057 |
Drug ineffective | 118.18 | 22.52 | 236 | 4240 | 819097 | 49781551 |
Confusional state | 103.26 | 22.52 | 103 | 4373 | 185825 | 50414823 |
Encephalopathy | 88.59 | 22.52 | 48 | 4428 | 33663 | 50566985 |
Renal graft infection | 68.80 | 22.52 | 12 | 4464 | 150 | 50600498 |
Mental status changes | 59.28 | 22.52 | 38 | 4438 | 36234 | 50564414 |
Product use in unapproved indication | 54.81 | 22.52 | 59 | 4417 | 115760 | 50484888 |
Clostridium difficile infection | 52.66 | 22.52 | 31 | 4445 | 25408 | 50575240 |
Avian influenza | 49.92 | 22.52 | 8 | 4468 | 57 | 50600591 |
Status epilepticus | 49.43 | 22.52 | 24 | 4452 | 13382 | 50587266 |
Mitochondrial toxicity | 47.59 | 22.52 | 10 | 4466 | 348 | 50600300 |
Skin odour abnormal | 42.43 | 22.52 | 12 | 4464 | 1460 | 50599188 |
Acute generalised exanthematous pustulosis | 42.24 | 22.52 | 19 | 4457 | 8919 | 50591729 |
Generalised tonic-clonic seizure | 41.58 | 22.52 | 27 | 4449 | 26283 | 50574365 |
Epilepsy | 41.29 | 22.52 | 25 | 4451 | 21542 | 50579106 |
Delirium | 38.97 | 22.52 | 30 | 4446 | 38162 | 50562486 |
Clostridium test positive | 38.38 | 22.52 | 12 | 4464 | 2060 | 50598588 |
Drug reaction with eosinophilia and systemic symptoms | 37.32 | 22.52 | 26 | 4450 | 28398 | 50572250 |
Bone marrow eosinophilic leukocyte count increased | 33.24 | 22.52 | 5 | 4471 | 22 | 50600626 |
Allergic hepatitis | 32.24 | 22.52 | 5 | 4471 | 28 | 50600620 |
Wound secretion | 31.20 | 22.52 | 12 | 4464 | 3805 | 50596843 |
Hallucination, visual | 31.17 | 22.52 | 19 | 4457 | 16563 | 50584085 |
Urinary tract infection pseudomonal | 29.97 | 22.52 | 8 | 4468 | 785 | 50599863 |
Klebsiella infection | 29.93 | 22.52 | 14 | 4462 | 7180 | 50593468 |
Tooth discolouration | 29.16 | 22.52 | 8 | 4468 | 871 | 50599777 |
Neurotoxicity | 27.99 | 22.52 | 17 | 4459 | 14723 | 50585925 |
Enterococcal infection | 27.40 | 22.52 | 13 | 4463 | 6885 | 50593763 |
Cross sensitivity reaction | 26.69 | 22.52 | 9 | 4467 | 1960 | 50598688 |
Pathogen resistance | 26.58 | 22.52 | 12 | 4464 | 5677 | 50594971 |
Hypoglycaemia | 26.54 | 22.52 | 28 | 4448 | 53553 | 50547095 |
Escherichia test positive | 26.09 | 22.52 | 9 | 4467 | 2098 | 50598550 |
Seizure like phenomena | 23.71 | 22.52 | 7 | 4469 | 991 | 50599657 |
Choriocarcinoma | 23.48 | 22.52 | 4 | 4472 | 43 | 50600605 |
Scar | 23.39 | 22.52 | 14 | 4462 | 11804 | 50588844 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Confusional state | 219.01 | 22.49 | 173 | 4567 | 127704 | 29442083 |
Seizure | 208.35 | 22.49 | 148 | 4592 | 92975 | 29476812 |
Hallucination | 130.56 | 22.49 | 84 | 4656 | 44628 | 29525159 |
Encephalopathy | 104.83 | 22.49 | 64 | 4676 | 30979 | 29538808 |
Hallucination, visual | 89.38 | 22.49 | 45 | 4695 | 14970 | 29554817 |
Myoclonus | 85.47 | 22.49 | 42 | 4698 | 13267 | 29556520 |
Delirium | 79.46 | 22.49 | 59 | 4681 | 39338 | 29530449 |
Product use in unapproved indication | 69.03 | 22.49 | 77 | 4663 | 86798 | 29482989 |
Generalised tonic-clonic seizure | 65.93 | 22.49 | 40 | 4700 | 19099 | 29550688 |
Status epilepticus | 51.76 | 22.49 | 28 | 4712 | 10766 | 29559021 |
Serotonin syndrome | 51.23 | 22.49 | 33 | 4707 | 17479 | 29552308 |
Pathogen resistance | 47.32 | 22.49 | 24 | 4716 | 8092 | 29561695 |
Epilepsy | 47.28 | 22.49 | 32 | 4708 | 18400 | 29551387 |
Biliary sepsis | 46.43 | 22.49 | 12 | 4728 | 568 | 29569219 |
Agitation | 41.57 | 22.49 | 46 | 4694 | 51258 | 29518529 |
Drug interaction | 41.53 | 22.49 | 95 | 4645 | 197290 | 29372497 |
Neurotoxicity | 41.42 | 22.49 | 27 | 4713 | 14586 | 29555201 |
Clostridium difficile colitis | 41.38 | 22.49 | 26 | 4714 | 13186 | 29556601 |
Toxic encephalopathy | 40.24 | 22.49 | 18 | 4722 | 4594 | 29565193 |
Disorientation | 39.87 | 22.49 | 35 | 4705 | 29480 | 29540307 |
Myasthenia gravis crisis | 38.54 | 22.49 | 10 | 4730 | 481 | 29569306 |
Pseudomonal sepsis | 37.39 | 22.49 | 15 | 4725 | 2927 | 29566860 |
Neuromyopathy | 36.84 | 22.49 | 11 | 4729 | 888 | 29568899 |
Drug resistance | 34.13 | 22.49 | 28 | 4712 | 21512 | 29548275 |
Eosinophilia | 31.38 | 22.49 | 27 | 4713 | 22134 | 29547653 |
Appendicitis perforated | 29.95 | 22.49 | 11 | 4729 | 1692 | 29568095 |
Rash morbilliform | 25.88 | 22.49 | 11 | 4729 | 2482 | 29567305 |
Metabolic acidosis | 24.20 | 22.49 | 30 | 4710 | 37632 | 29532155 |
Vitamin B1 deficiency | 23.80 | 22.49 | 6 | 4734 | 257 | 29569530 |
Vitamin A deficiency | 23.32 | 22.49 | 4 | 4736 | 23 | 29569764 |
Anticonvulsant drug level decreased | 23.30 | 22.49 | 8 | 4732 | 1011 | 29568776 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Confusional state | 300.19 | 19.65 | 256 | 8053 | 260888 | 64229535 |
Seizure | 280.82 | 19.65 | 205 | 8104 | 166687 | 64323736 |
Hallucination | 251.61 | 19.65 | 141 | 8168 | 72647 | 64417776 |
Encephalopathy | 184.48 | 19.65 | 107 | 8202 | 58712 | 64431711 |
Delirium | 118.21 | 19.65 | 86 | 8223 | 69108 | 64421315 |
Hallucination, visual | 112.82 | 19.65 | 60 | 8249 | 27774 | 64462649 |
Myoclonus | 107.06 | 19.65 | 56 | 8253 | 25062 | 64465361 |
Product use in unapproved indication | 101.19 | 19.65 | 119 | 8190 | 176499 | 64313924 |
Generalised tonic-clonic seizure | 100.29 | 19.65 | 63 | 8246 | 39794 | 64450629 |
Status epilepticus | 97.21 | 19.65 | 50 | 8259 | 21613 | 64468810 |
Epilepsy | 89.40 | 19.65 | 55 | 8254 | 33476 | 64456947 |
Mental status changes | 71.90 | 19.65 | 61 | 8248 | 61101 | 64429322 |
Pathogen resistance | 68.23 | 19.65 | 33 | 8276 | 12510 | 64477913 |
Neurotoxicity | 68.12 | 19.65 | 43 | 8266 | 27361 | 64463062 |
Clostridium difficile infection | 64.10 | 19.65 | 46 | 8263 | 36117 | 64454306 |
Clostridium test positive | 60.52 | 19.65 | 22 | 8287 | 4093 | 64486330 |
Clostridium difficile colitis | 58.53 | 19.65 | 39 | 8270 | 27184 | 64463239 |
Renal graft infection | 53.08 | 19.65 | 12 | 8297 | 401 | 64490022 |
Drug reaction with eosinophilia and systemic symptoms | 49.69 | 19.65 | 47 | 8262 | 54170 | 64436253 |
Disorientation | 48.52 | 19.65 | 47 | 8262 | 55781 | 64434642 |
Toxic encephalopathy | 47.94 | 19.65 | 24 | 8285 | 9791 | 64480632 |
Drug resistance | 45.36 | 19.65 | 37 | 8272 | 35065 | 64455358 |
Avian influenza | 44.58 | 19.65 | 8 | 8301 | 79 | 64490344 |
Eosinophilia | 42.73 | 19.65 | 37 | 8272 | 38039 | 64452384 |
Agitation | 40.01 | 19.65 | 53 | 8256 | 88314 | 64402109 |
Cross sensitivity reaction | 38.60 | 19.65 | 15 | 8294 | 3352 | 64487071 |
Myasthenia gravis crisis | 34.87 | 19.65 | 10 | 8299 | 874 | 64489549 |
Acute generalised exanthematous pustulosis | 34.77 | 19.65 | 22 | 8287 | 14036 | 64476387 |
Neuromyopathy | 34.66 | 19.65 | 11 | 8298 | 1357 | 64489066 |
Biliary sepsis | 34.19 | 19.65 | 11 | 8298 | 1417 | 64489006 |
Bone marrow eosinophilic leukocyte count increased | 31.36 | 19.65 | 5 | 8304 | 22 | 64490401 |
Skin odour abnormal | 31.30 | 19.65 | 11 | 8298 | 1856 | 64488567 |
Eosinophilic pneumonia | 30.94 | 19.65 | 14 | 8295 | 4563 | 64485860 |
Escherichia test positive | 30.32 | 19.65 | 12 | 8297 | 2813 | 64487610 |
Allergic hepatitis | 29.92 | 19.65 | 5 | 8304 | 31 | 64490392 |
Tooth discolouration | 29.67 | 19.65 | 9 | 8300 | 956 | 64489467 |
Pseudomonal sepsis | 29.31 | 19.65 | 14 | 8295 | 5158 | 64485265 |
Disorganised speech | 28.73 | 19.65 | 10 | 8299 | 1640 | 64488783 |
Metabolic acidosis | 28.24 | 19.65 | 40 | 8269 | 70918 | 64419505 |
Fatigue | 27.24 | 19.65 | 34 | 8275 | 748696 | 63741727 |
Pyrexia | 26.77 | 19.65 | 142 | 8167 | 558502 | 63931921 |
Urinary tract infection pseudomonal | 26.16 | 19.65 | 9 | 8300 | 1425 | 64488998 |
Seizure like phenomena | 24.92 | 19.65 | 9 | 8300 | 1643 | 64488780 |
Arthralgia | 24.88 | 19.65 | 13 | 8296 | 442247 | 64048176 |
Vitamin B1 deficiency | 24.86 | 19.65 | 7 | 8302 | 573 | 64489850 |
Drug interaction | 24.64 | 19.65 | 102 | 8207 | 361981 | 64128442 |
Anticonvulsant drug level decreased | 24.02 | 19.65 | 9 | 8300 | 1821 | 64488602 |
Mitochondrial toxicity | 23.92 | 19.65 | 10 | 8299 | 2696 | 64487727 |
Metabolic encephalopathy | 23.53 | 19.65 | 14 | 8295 | 8011 | 64482412 |
Appendicitis perforated | 23.52 | 19.65 | 10 | 8299 | 2810 | 64487613 |
Rash morbilliform | 23.43 | 19.65 | 12 | 8297 | 5129 | 64485294 |
Wound secretion | 23.24 | 19.65 | 12 | 8297 | 5220 | 64485203 |
Enterococcal infection | 23.10 | 19.65 | 17 | 8292 | 13849 | 64476574 |
Off label use | 22.66 | 19.65 | 149 | 8160 | 632657 | 63857766 |
Pain in extremity | 21.87 | 19.65 | 6 | 8303 | 303079 | 64187344 |
Klebsiella infection | 21.49 | 19.65 | 16 | 8293 | 13265 | 64477158 |
Unresponsive to stimuli | 20.93 | 19.65 | 29 | 8280 | 50364 | 64440059 |
Vitamin A deficiency | 20.62 | 19.65 | 4 | 8305 | 62 | 64490361 |
Choriocarcinoma | 20.62 | 19.65 | 4 | 8305 | 62 | 64490361 |
Endotracheal intubation | 20.43 | 19.65 | 10 | 8299 | 3885 | 64486538 |
Haematidrosis | 20.39 | 19.65 | 4 | 8305 | 66 | 64490357 |
HER2 positive breast cancer | 19.93 | 19.65 | 5 | 8304 | 262 | 64490161 |
None
Source | Code | Description |
---|---|---|
ATC | J01DH03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems |
FDA CS | M0024174 | Carbapenems |
FDA EPC | N0000175496 | Penem Antibacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acute bacterial peritonitis | indication | 31860008 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Miscarriage with sepsis | indication | 67465009 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Abdominal abscess | indication | 75100008 | |
Female genital tract infection | indication | 125585007 | |
Infectious disease of abdomen | indication | 128070006 | |
Pneumococcal pneumonia | indication | 233607000 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Peptostreptococcus infection | indication | 135341000119101 | |
Urinary tract infection caused by Klebsiella | indication | 369001000119100 | |
Complicated Bacterial Peritonitis | indication | ||
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection | indication | ||
Septic Abortion due to Porphyromonas | indication | ||
Post-Op Gynecologic Infection due to Porphyromonas | indication | ||
Klebsiella Pyelonephritis | indication | ||
Post-Op Gynecological Peptostreptococcus Infection | indication | ||
Complicated E. Coli Peritonitis | indication | ||
Postpartum Endomyometritis due to E. Coli | indication | ||
Postpartum Endomyometritis due to Streptococcus | indication | ||
Diabetic Foot Infection | indication | ||
Streptococcal Septic Abortion | indication | ||
Postpartum Endomyometritis due to Peptostreptococcus | indication | ||
Post-Op Gynecologic Infection due to Bacteroides | indication | ||
Postpartum Endomyometritis due to Bacteroides | indication | ||
E. Coli Septic Abortion | indication | ||
E. Coli Pyelonephritis | indication | ||
Complicated Skin and Skin Structure Staphylococcus Aureus Infection | indication | ||
Complicated Skin and Skin Structure E. Coli Infection | indication | ||
Peptostreptococcus Septic Abortion | indication | ||
Complicated Bacteroides Peritonitis | indication | ||
Moraxella Catarrhalis Pneumonia | indication | ||
Post-Op Gynecologic Infection due to Prevotella | indication | ||
Bacteroides Septic Abortion | indication | ||
Colorectal Surgery Infection Prevention | indication | ||
Postpartum Endomyometritis due to Porphyromonas | indication | ||
Post-Op Gynecological Infection due to E. Coli | indication | ||
Postpartum Endomyometritis due to Prevotella | indication | ||
Post-Op Gynecologic Infection, due to Streptococcus | indication | ||
Prevotella Septic Abortion | indication | ||
Complicated Skin and Skin Structure Infection | indication | ||
Gas gangrene caused by clostridium perfringens | off-label use | 266093005 | |
Clostridium Perfringens Empyema | off-label use | ||
Acute nephropathy | contraindication | 58574008 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Seizure disorder | contraindication | 128613002 | |
Lesion of brain | contraindication | 301766008 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.79 | acidic |
pKa2 | 4.1 | acidic |
pKa3 | 6.83 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D-alanyl-D-alanine carboxypeptidase DacB | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
Penicillin-binding protein 1A | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
Penicillin-binding protein 1B | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
Penicillin-binding protein 1 | Enzyme | WOMBAT-PK | |||||||
Penicillin-binding protein 2 | Enzyme | WOMBAT-PK | |||||||
D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6 | Enzyme | WOMBAT-PK | |||||||
Penicillin-binding protein 4 | Enzyme | WOMBAT-PK | |||||||
D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5 | Enzyme | WOMBAT-PK |
ID | Source |
---|---|
4021283 | VUID |
N0000148720 | NUI |
D04049 | KEGG_DRUG |
153773-82-1 | SECONDARY_CAS_RN |
4021283 | VANDF |
C1120106 | UMLSCUI |
CHEBI:404903 | CHEBI |
CHEMBL1359 | ChEMBL_ID |
CHEMBL1232 | ChEMBL_ID |
D000077727 | MESH_DESCRIPTOR_UI |
DB00303 | DRUGBANK_ID |
10906 | IUPHAR_LIGAND_ID |
8049 | INN_ID |
G32F6EID2H | UNII |
150610 | PUBCHEM_CID |
325642 | RXNORM |
16218 | MMSL |
173352 | MMSL |
274067 | MMSL |
42474 | MMSL |
d04783 | MMSL |
009554 | NDDF |
009555 | NDDF |
385573008 | SNOMEDCT_US |
385574002 | SNOMEDCT_US |
396346003 | SNOMEDCT_US |
1RG | PDB_CHEM_ID |
2RG | PDB_CHEM_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
INVANZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3843 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 28 sections |
INVANZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3843 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 28 sections |
INVANZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3845 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 28 sections |
INVANZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3845 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 28 sections |
ertapenem sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9398 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 28 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-3510 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 28 sections |
ERTAPENEM SODIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-889 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
ERTAPENEM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-221 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 29 sections |
ERTAPENEM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-221 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 29 sections |
ERTAPENEM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-221 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 29 sections |
ERTAPENEM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-221 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 29 sections |
ERTAPENEM SODIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-901 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-820 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 28 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44647-051 | INJECTION | 1 g | INTRAVENOUS | ANDA | 29 sections |
Ertapenem | Human Prescription Drug Label | 1 | 55150-282 | INJECTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
Ertapenem | Human Prescription Drug Label | 1 | 55150-282 | INJECTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
Ertapenem | Human Prescription Drug Label | 1 | 55150-282 | INJECTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6196 | INJECTION | 1 g | INTRAVENOUS | ANDA | 29 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6196 | INJECTION | 1 g | INTRAVENOUS | ANDA | 29 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-823 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 29 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68001-408 | INJECTION | 1 g | INTRAVENOUS | ANDA | 29 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68001-408 | INJECTION | 1 g | INTRAVENOUS | ANDA | 29 sections |
Ertapenem | Human Prescription Drug Label | 1 | 68083-351 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
Ertapenem | Human Prescription Drug Label | 1 | 68083-351 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72266-159 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72266-159 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 25 sections |